News
-
-
PRESS RELEASE
2025 half-year results: Strategic enhancement of the offering and stable operating income in a complex and uncertain economic environment
Fermentalg presents its 2025 half-year results showing revenue growth and stable operating income. Expansion in BioSolutions portfolio and markets, strategic agreements, and FDA approval highlighted -
-
-
-
-
-
PRESS RELEASE
Fermentalg continues on its path of development trajectory with sales of 7.6M EUR for the 1st half of 2025
Fermentalg reports 20% sales growth in 1st half of 2025 with €7.6 million revenue, driven by Ωrigins™ range. Expansion into pet food, infant nutrition, aquaculture. Approval of Galdieria Blue as natural food colorant by FDA. Target sales of €25 million by 2026. Full repayment of convertible bonds -
-